Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19

#	Paper	IF	Citations
22	Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. *Clinical Infectious Diseases*, **2021**, 73, e4082-e4089	11.6	13
21	Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. *Baillieres Best Practice and Research in Clinical Anaesthesiology*, **2021**, 35, 269-292	4	4
20	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. *Frontiers in Pharmacology*, **2020**, 11, 559996	5.6	1
19	Will Evidence-based Medicine Survive the COVID-19 Pandemic?. *Annals of the American Thoracic Society*, **2020**, 17, 1060-1061	4.7	4
18	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 324, 2165-2176	27.4	206
17	Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science. *JAMA - Journal of the American Medical Association*, **2020**, 324, 2161-2162	27.4	43
16	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. *International Journal of Antimicrobial Agents*, **2021**, 57, 106222	14.3	13
15	Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape. *Clinical Trials*, **2021**, 18, 324-334	2.2	3
14	What can a learning healthcare system teach us about improving outcomes?. *Current Opinion in Critical Care*, **2021**, 27, 527-536	3.5	1
13	Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials. *Journal of Biopharmaceutical Statistics*, **2021**, 1-23	1.3	2
12	Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?. *Journal of Parenteral and Enteral Nutrition*, **2021**, 45, 1690-1702	4.2	1
11	Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. *Indian Journal of Pharmacology*, **2020**, 52, 414-421	2.5	15
10	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. *European Journal of Internal Medicine*, **2021**,	3.9	0
9	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. *Journal of Clinical Pharmacology*, **2021**,	2.9	1
8	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.. *Infection, Genetics and Evolution*, **2022**, 99, 105254	4.5	2
7	Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19.. *Frontiers in Medicine*, **2022**, 9, 829423	4.9	1
6	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. *Lancet Respiratory Medicine,the*, **2022**,	35.1	1

5	Optimizing the Design and Analysis of Future AKI Trials. *Journal of the American Society of Nephrology: JASN*, ASN.2021121605	12.7	0
4	Bayesian adaptive clinical trial designs for respiratory medicine.		0
3	Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19. 12,		0
2	Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring. **2023**, 23,		0
1	A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. **2023**, 11, 332		0